Sign In
Buy IMUX
$13.97
-0.0200 (-0.143%)
At Close: Jul 31, 2026
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
06:30am, Thursday, 13'th Nov 2025
– Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41st Congress of ECTRIMS – – Phase 2 CALLIPER Data Demonstrated Statistically Significan
Immunic CEO discusses MS focus, upcoming Phase 3 trial readouts - ICYMI
09:48am, Saturday, 08'th Nov 2025
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's strong presence at BIO-Europe 2025 and the growing momentum behind its late-stage clinical programs. Vitt discuss
Immunic to Participate in Industry and Investor Conferences in November
06:30am, Wednesday, 29'th Oct 2025
NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflamma
Immunic targeting mental and physical challenges facing MS patients - ICYMI
10:33am, Saturday, 11'th Oct 2025
Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Dr Hella Kohlhof talked with Proactive about the company's research focus on multiple sclerosis (MS), highlighting how Immunic is aiming to address b
Immunic to Participate in Scientific and Investor Conferences in October
06:30am, Wednesday, 01'st Oct 2025
NEW YORK , Oct. 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammat
Immunic is aiming for a big breakthrough in the treatment of multiple sclerosis
11:40am, Monday, 29'th Sep 2025
An unheralded New York–listed biotech is chasing one of neurology's biggest goals: a pill that not only tamps down the inflammatory flares of multiple sclerosis but also directly protects the brain
Immunic highlights multiple sclerosis drug findings at key neurology gathering
08:07am, Thursday, 25'th Sep 2025
Immunic Inc (NASDAQ:IMUX) has presented clinical trial data suggesting its oral therapy, vidofludimus calcium, could help slow disability in patients with progressive multiple sclerosis, a form of the
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
06:30am, Thursday, 25'th Sep 2025
– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Ove
Immunic secures US patent protection for vidofludimus calcium in dose strengths in progressive MS
08:56am, Tuesday, 09'th Sep 2025
Immunic Inc (NASDAQ:IMUX) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) covering dose strengths of its lead asset, vidofludimus calciu
– Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Comprehensive Intellectual Property Strategy Secures Protection Into 2041 in the U.S., Unless Extended Furth
Immunic to Participate in Investor and Scientific Conferences in September
06:30am, Thursday, 04'th Sep 2025
NEW YORK , Sept. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammato
Immunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMI
08:14am, Saturday, 09'th Aug 2025
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's second quarter highlights, with a particular focus on clinical progress in its multiple sclerosis (MS) programs.
Immunic advances MS drug program with Phase 3 trials fully enrolled
08:27am, Thursday, 07'th Aug 2025
Immunic Inc (NASDAQ:IMUX) said on Thursday it has fully enrolled its twin Phase 3 ENSURE trials for vidofludimus calcium, positioning the company for a major data readout by end-2026 in relapsing mult
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
06:30am, Thursday, 07'th Aug 2025
– Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis Study Population and Across Subtypes, Reinfor
Immunic CEO discusses Phase 2 multiple sclerosis study success - ICYMI
09:05am, Saturday, 28'th Jun 2025
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about new positive data from the company's phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (
